Antiviral compounds
Use of certain castanospermine esters in the treatment of diseases caused by flaviviruses, in particular in the treatment of disease caused by the hepatitis C virus (HCV) and compositions containing said esters in combination with adjunctive therapeutic agents.
1. A method for treating a Hepacivirus infection, said method comprising the step of administering to a patient a therapeutic composition comprising (i) an agent that alters immune function, and (ii) a glucosidase inhibitor wherein the agent that alters immune function is an interferon and the glucosidase inhibitor is [1S-(1α,6β,7α,8β,8αβ)]-octahydro-1 6,7,8-indolizinetetrol 6-butanoate.
2. The method according to claim 1 wherein the patient is a human.
3. The method according to claim 1 wherein the interferon is an α-interferon.
4. The method according to claim 1 wherein said Hepacivirus is Hepatitis C virus.
5. The method according to claim 1 wherein the composition further comprises a pharmaceutically acceptable excipient.
6. A method for treating a Hepacivirus infection, said method comprising the step of administering to a patient a therapeutic composition comprising (i) an agent that alters viral replication, and (ii) a glucosidase inhibitor wherein the agent that alters replication is ribavirin and the glucosidase inhibitor is [1S-(1α,6β,7α,8β,8αβ)]-octahydro-1 6,7,8-indolizinetetrol 6-butanoate.
7. The method according to claim 6 wherein the patient is a human.
8. The method according to claim 6 wherein said Hepacivirus is Hepatitis C virus.
9. The method according to claim 6 wherein the composition further comprises a pharmaceutically acceptable excipient.
10. A method for treating a Hepacivirus infection, said method comprising the step of administering to a patient a therapeutic composition comprising a glucosidase inhibitor, wherein the glucosidase inhibitor is [1S-(1α,6β,7α,8β,8αβ)]-octahydro-1 6,7,8-indolizinetetrol 6-butanoate.
11. The method according to claim 10 wherein said Hepacivirus is Hepatitis C virus.
12. The method according to claim 10 wherein the composition further comprises a pharmaceutically acceptable excipient.